Proteome-based identification and validation of NXPE3 in childhood acute lymphoblastic leukaemia
A new blood protein shows promise for spotting which children with leukemia need brain monitoring, though larger studies are needed.
LC-MS/MS proteomics and ELISA validation in 15 pediatric ALL patients (3 risk groups) identified NXPE3 as a novel plasma protein elevated in B-ALL standard risk, proposed as a biomarker for CNS infiltration assessment. This is the first report of NXPE3 in childhood ALL, but the extremely small sample size (n=15) limits conclusions.
What the study was
- Study design
- Proteomics discovery + ELISA validation study
- Population
- Pediatric ALL patients (B-ALL SR, B-ALL HR, T-ALL HR) with healthy controls
- Sample size
- 15
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Pakistan Journal of Pharmaceutical Sciences
Why it surfaced
Novel biomarker for CNS infiltration in pediatric ALL (high clinical unmet need) but n=15 is critically small; first report requires independent validation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.